[PDF][PDF] Targeting GARP: TGF-β1 complexes on Tregs for the immunotherapy of myeloproliferative neoplasms

J Devreux - 2022 - dial.uclouvain.be
Philadelphia-negative myeloproliferative neoplasms (MPNs) regroup hematological
malignancies arising from the clonal expansion of a hematopoietic stem cell (HSC) and lead …

Therapeutic activity of GARP: TGF-β1 blockade in murine primary myelofibrosis

S Lecomte, J Devreux, G de Streel, N van Baren… - Blood, 2023 - ashpublications.org
Primary myelofibrosis (PMF) is a myeloproliferative neoplasm characterized by the clonal
expansion of myeloid cells, notably megakaryocytes (MKs), and an aberrant cytokine …

[PDF][PDF] Therapeutic activity of GARP: TGF-β1 blockade in murine primary myelofibrosis

T TGF - dial.uclouvain.be
Primary myelofibrosis (PMF) is a myeloproliferative neoplasm characterized by the clonal
expansion of myeloid cells, notably megakaryocytes (MKs), and an aberrant cytokine …

[HTML][HTML] Selective targeting of GARP-LTGFβ axis in the tumor microenvironment augments PD-1 blockade via enhancing CD8+ T cell antitumor immunity

A Li, Y Chang, NJ Song, X Wu, D Chung… - … for Immunotherapy of …, 2022 - ncbi.nlm.nih.gov
Background Immune checkpoint blockade (ICB) has revolutionized cancer immunotherapy.
However, most patients with cancer fail to respond clinically. One potential reason is the …

18 Generation and validation of humanized GARP/TGFB1 mice for testing novel anti-human GARP antibodies

Z Niu, X Zhou, R Lv, J Li, Y Shen - 2023 - jitc.bmj.com
Background Checkpoint inhibitors targeting PD-1 or PD-L1 are at the forefront of cancer
immunotherapy, however, treating tumors that have primary or acquired resistance to PD …

Combined Blockade of GARP: TGF-b1 and PD-1 Increases Infiltration of T Covered Cells and GARP+ Density Blood of Pericyte-Vessels in Mouse MC38 Tumors

C Bertrand, P Van Meerbeeck… - … : From Efficacy to …, 2022 - books.google.com
MATERIALS AND METHODS TGF-β1 is a potent immunosuppressive cytokine produced by
most cells in an inactive, latent form. In its latent form, the mature TGF-β1 dimer is non …

Monoclonal antibodies against GARP/TGF-β1 complexes inhibit the immunosuppressive activity of human regulatory T cells in vivo

J Cuende, S Liénart, O Dedobbeleer… - Science translational …, 2015 - science.org
Regulatory T cells (Tregs) are essential to prevent autoimmunity, but excessive Treg function
contributes to cancer progression by inhibiting antitumor immune responses. Tregs exert …

Selective inhibition of TGF-β1 produced by GARP-expressing Tregs overcomes resistance to PD-1/PD-L1 blockade in cancer

G de Streel, C Bertrand, N Chalon, S Liénart… - Nature …, 2020 - nature.com
Abstract TGF-β1, β2 and β3 bind a common receptor to exert vastly diverse effects in cancer,
supporting either tumor progression by favoring metastases and inhibiting anti-tumor …

Garp as a therapeutic target for modulation of T regulatory cell function

EM Shevach - Expert opinion on therapeutic targets, 2017 - Taylor & Francis
Introduction: Foxp3+ T regulatory cells (Tregs) play critical roles in immune homeostasis
primarily by suppressing many aspects of the immune response. Tregs uniquely express …

Generation and validation of humanized GARP mice for testing novel anti-human GARP antibodies

R Lyu, H Li, J Frame, Y Shen - Cancer Research, 2022 - AACR
GARP is a type I transmembrane protein expressed on regulatory T cells (Tregs) and
platelets. GARP expression has been shown to play an important role in the modulation of …